Revue des maladies respiratoires · 2026
[The clinical impact of frailty in fibrotic interstitial lung diseases].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Menigoz C, Huet J, Dirou S
Аннотация
INTRODUCTION: Frailty is a complex and multidimensional clinical syndrome characterized by decreased physiological reserves. It, results in increased susceptibility to adverse health outcomes. In 2001, Fried et al. established the phenotypic diagnostic criteria for frailty. Owing to the frequency, prognostic implications, and potential reversibility of frailty, systematic screening is recommended for all individuals over the age of 65. Several tools are currently available for the purposes of screening, assessment, and diagnosis.
STATE OF THE ART: Fibrotic interstitial lung diseases (ILDs) occur predominantly in elderly patients. The reported prevalence of frailty in this population varies depending on the diagnostic criteria employed. In a prospective cohort of more than 1,500 patients, Guler et al. demonstrated that frailty was associated with a heightened risk of mortality and functional decline. In a related study, the same team reported that frailty was associated with a higher risk of antifibrotic dose reduction and deteriorated quality of life.
PERSPECTIVES: These findings suggest that enhanced recognition and management of frailty could help optimize therapeutic care and improve the quality of life of patients with fibrotic ILDs.
STATE OF THE ART: Fibrotic interstitial lung diseases (ILDs) occur predominantly in elderly patients. The reported prevalence of frailty in this population varies depending on the diagnostic criteria employed. In a prospective cohort of more than 1,500 patients, Guler et al. demonstrated that frailty was associated with a heightened risk of mortality and functional decline. In a related study, the same team reported that frailty was associated with a higher risk of antifibrotic dose reduction and deteriorated quality of life.
PERSPECTIVES: These findings suggest that enhanced recognition and management of frailty could help optimize therapeutic care and improve the quality of life of patients with fibrotic ILDs.